29 Results for "

KCNQ2

" in MedChemExpress (MCE) Product Catalog:
Products (29)

29 Results for "KCNQ2" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-108577
CAS No.: 122955-13-9
Purity:  99.63%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

XE991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-108577A
CAS No.: 122955-42-4
Purity:  99.62%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

XE 991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-101396
CAS No.: 582323-16-8
Purity:  99.20%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

ICA-069673 is a KCNQ2/Q3 potassium channel activator. ICA-069673 demonstrates greater selectivity for KV7.2/7.3 over KV7.3/KV7.5, with EC50s of 0.69 μM and 14.3 μM, respectively. ICA-069673 inhibits spontaneous phasic and nerve-evoked contractions in guinea pig detrusor smooth muscle (DSM). ICA-069673 also decreases the global intracellular Ca(2+) concentration in DSM cells [2].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-122114
CAS No.: 325457-89-4
Purity:  99.27%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

ICA-27243 is a selective, potent and orally active KCNQ2/Q3 potassium channel opener with an EC50 of 0.38 μM. ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 has antiepileptic and anticonvulsant effects [2].
loading...
    loading...
Cat. No.: HY-18063
CAS No.: 1392494-64-2
Research Areas:  

Neurological Disease

ML252 is a selective inhibitor of KCNQ2 (Kv7.2) channel with an IC50s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3 and KCNQ4, respectively. ML252 also inhibits Cytochrome P450 with IC50s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 shows highly brain penetrant [2].
loading...
    loading...
Cat. No.: HY-108587
CAS No.: 325457-99-6
Purity:  99.85%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

ICA 110381 is an orally active Kv7.2/Kv7.3 (KCNQ2/3) potassium channel activator with anticonvulsive properties. ICA 110381 is a KCNQ2/Q3 activator (EC50=0.38 μM) as well as KCNQ1 antagonist (IC50=15 μM) .
loading...
    loading...
Cat. No.: HY-157485
CAS No.: 339287-36-4
Purity:  99.99%
Target:  

Potassium Channel

Research Areas:  

Others

Ebio1 is a selective voltage-gated potassium channel KCNQ2 activator. Ebio1 activates KCNQ2 by generating an extended channel gate with greater conductance at a saturation voltage (+50 mV) .
loading...
    loading...
Cat. No.: HY-145016
CAS No.: 1821222-10-9
Purity:  99.53%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

HN37 as a potent and chemically stable antiepileptic agent candidate, with an EC50 of 37 nM for KCNQ2 . HN37 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-123264
CAS No.: 1919050-87-5
Purity:  99.20%
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

RL648_81 is a specific KQT-like subfamily 2/3 (KCNQ2/3) activator with an EC50 of 190 nM. RL648_81 robustly shifts the V1/2 of KCNQ2/3 channels towards hyperpolarized potentials.RL648_81 does not shift the V1/2 of either KCNQ4 or KCNQ5.RL648_81 has?the?potential?for?neurologic disorders associated with neuronal hyperexcitability research .
loading...
    loading...
Cat. No.: HY-108592
CAS No.: 918311-87-2
Purity:  98.91%
UCL 2077 is a potassium channel and slow afterhyperpolarization (sAHP) inhibitor. UCL 2077 selectively blocks sAHP channels without affecting L-type Ca 2+ currents. UCL 2077 blocks KCNQ1- and KCNQ2-containing K + channels, decreases erg current amplitude, increases erg deactivation rate. UCL 2077 can be used for the research of hippocampus-dependent memory retrieval deficit and cardiac arrhythmias [2] .
loading...
    loading...
Cat. No.: HY-113616A
CAS No.: 1240514-89-9
Purity:  99.27%
Target:  

MARCKS mAChR

Research Areas:  

Neurological Disease

VU0364572 TFA is an orally active and selective allosteric agonist of the M1 muscarinic receptor with an EC50 of 0.11 μM. VU0364572 TFA has neuroprotective potential for preventing memory impairments and reducing neuropathology in Alzheimer’s Disease. VU0364572 TFA is CNS penetrant .
loading...
    loading...
Cat. No.: HY-RS07174
Research Areas:  

Others

KCNQ2 Human Pre-designed siRNA Set A contains three designed siRNAs for KCNQ2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-180873
CAS No.: 462617-36-3
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

KCNQ2 modulator-1 is a KCNQ2 modulator.
loading...
    loading...
Cat. No.: HY-RS17110
Research Areas:  

Others

Kcnq2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kcnq2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS23555
Research Areas:  

Others

Kcnq2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Kcnq2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-172140
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

Ebio3 is a selective potassium channel (KCNQ2) inhibitor with an IC50 of 1.2 nM. Ebio3 binds to the KCNQ2 channel through its hydrophobic tail, causing the S6 helix to move inward, which leads to the closure of the inner gate. The inhibitory effect of Ebio3 is also effective in pathogenic mutants of KCNQ2 (such as R75C and I238L), where it can inhibit outward currents by more than 80%. Ebio3 is expected to be used in the research of neurological diseases such as epilepsy .
loading...
    loading...
Cat. No.: HY-115823
CAS No.: 325457-98-5
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

ztz240 is a chemical modulator of voltage-gated potassium channel Kv7 (KCNQ) (KCNQ2 and 3: EC50=6.1 μM; KCNQ4: EC50=12.2 μM). ztz240 can be used in analgesia and anti-epileptic research .
loading...
    loading...
Cat. No.: HY-18063A
CAS No.: 2309887-61-2
Research Areas:  

Neurological Disease

ML252 hydrochloride is a selective inhibitor of KCNQ2 (Kv7.2) channel with IC50s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3 and KCNQ4, respectively. ML252 hydrochloride also inhibits Cytochrome P450 with IC50s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 hydrochloride shows highly brain penetrant [2].
loading...
    loading...
Cat. No.: HY-172141
Target:  

Potassium Channel

Research Areas:  

Cardiovascular Disease

Ebio2 is a potent KCNQ2 activator .
loading...
    loading...
Cat. No.: HY-181128
CAS No.: 2253948-15-9
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

QO-83, Retigabine analogue, is a voltage-gated potassium channel KCNQ2 (Kv7.2) activator with an EC50 of 0.56 μM. QO-83 binds to a single hydrophobic pocket of KCNQ2-CaM complex in closed conformation. QO-83 induces a negative shift in the voltage-dependent activation curve of KCNQ2 channels, increasing the channel's voltage sensitivity. QO-83 can be used for the research of epilepsies .
loading...
    loading...